$3.055
+0.119 (+3.91%)Al cierre
Comparativa sectorial de PBM
In the context of the broader market, PBM competes directly with industry leaders such as HIND and BOLT. With a market capitalization of $11.64M, it holds a significant position in the sector. When comparing efficiency, PBM's gross margin of N/A stands against HIND's 33.57% and BOLT's 100.00%. Such benchmarking helps identify whether Psyence Biomedical Ltd is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Psyence Biomedical Ltd
The financial performance shows a net income of 141,473 USD in Q3 2025, but a significant loss of -753,254 USD in Q2 2026. The current ratio is 8.09, indicating good short-term liquidity, but the debt-to-equity ratio is concerning at -199.26% in Q3 2025, suggesting financial instability.
Financials
Artículos relacionados
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.